Drugs / DBI-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05491603 | Nov 2023 | tinea unguium | DermBiont, Inc. | Suspended | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05493488 Comparator | Sep 2022 → Dec 2023 | tinea pedis | DermBiont, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04937920 Comparator | Mar → Sep 2021 | pityriasis versicolor | DermBiont, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DBI-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04937920 ↗ |
| Modality | Other / unclassified | “DBI-002 probiotic gel” NCT04937920 ↗ |
| Route | Topical | “Topical application of DBI-002 probiotic gel on skin affected with tinea versicolor” NCT04937920 ↗ |